Felipe de Arriba de la Fuente

Profesor Asociado

Universidad de Murcia

Spain

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Internal Medicine

100%

Immunology

60%

Hematology

80%

Multiple Myeloma

70%

Targeted Therapy

50%

Prognostic Biomarker

50%

Amyloidosis

40%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles16

The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression.

Article Link

Year:

2024

Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

Article Link

Year:

2024

Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study

Article Link

Year:

2024

LENALIDOMIDE AND DEXAMETHASONE WITH OR WITHOUT IXAZOMIB MAINTENANCE TAILORED BY RESIDUAL DISEASE STATUS IN MYELOMA

Article Link

Year:

2023

Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance

Article Link

Year:

2023

Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance–Like Phenotype in Patients With Monoclonal Gammopathies

Article Link

Year:

2023

Randomized phase II study of weekly carfilzomib 70 mg/m2 and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients.

Article Link

Year:

2023

Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection

Article Link

Year:

2023

A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma

Article Link

Year:

2022

Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma

Article Link

Year:

2022

A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma.

Article Link

Year:

2022

How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma

Article Link

Year:

2022

Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study

Article Link

Year:

2022

Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma.

Article Link

Year:

2022

Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development.

Article Link

Year:

2021

Minimal Residual Disease in Multiple Myeloma: Something Old, Something New.

Article Link

Year:

2021

Collaborators9

Verónica González-Calle

University Hospital of Salamanca

SPAIN

José María Bellón Cano

Instituto de Investigación Sanitaria Gregorio Marañón

SPAIN

Cristina Pérez Ruiz

Universidad de Navarra

SPAIN

Jesus F. San Miguel

SPAIN

Cirino Botta

Assistant Professor of Hematology

University of Palermo

ITALY

MJ Calasanz

Full Professor of Genetics

Universidad de Navarra

SPAIN

Enrique M. Ocio

SPAIN

Albert Oriol

Institut Català d'Oncologia

SPAIN

Pierpaolo Correale

Oncologist with a High Professional Thoracic Oncology Assignment

ITALY

How do I reach out?

Meet Kite AI